Skip to main content
      RT @ericdeinmd: Abst0326 #ACR22 Anti-Mitochondrial Ab in SLE
      Whole mitochondrial (AwMA), AmtDNA or AmtRNA - higher in SL

      Eric Dein ericdeinmd

      3 years 10 months ago
      Abst0326 #ACR22 Anti-Mitochondrial Ab in SLE Whole mitochondrial (AwMA), AmtDNA or AmtRNA - higher in SLE compared to controls AwMA predictive of death, AmtDNA and AmtRNA predictive of nephritis @Rheumnow https://t.co/d98HSHnJVE
      RT @ericdeinmd: Abst0328 #ACR22. Predicting UCTD to CTD Meta-Analysis
      Factors for SLE transition: younger age, serositis

      Eric Dein ericdeinmd

      3 years 10 months ago
      Abst0328 #ACR22. Predicting UCTD to CTD Meta-Analysis Factors for SLE transition: younger age, serositis, dsDNA SSc transition: puffy finger, NFC, or SSc antibodies No studies wo moderate or high risk of bias Limited studies on biomarkers for SLE, need more studies @Rheumnow https://t.co/GofGF8TkCx
      RT @ericdeinmd: All monster stories end with an unexpected award: A new order
      @cuttingforstone at #ACR22 tells the monst

      Eric Dein ericdeinmd

      3 years 10 months ago
      All monster stories end with an unexpected award: A new order @cuttingforstone at #ACR22 tells the monster story of #covid “How will history review our story?” The science will get an A+, but we failed to learn the lessons of history All was predictable through history @RheumNow
      RT @ericdeinmd: Year in Review #ACR22
      GLORIA
      Low steroid usage: lower DAS28, reduced joint damage
      BUT 24% increased adve

      Eric Dein ericdeinmd

      3 years 10 months ago
      Year in Review #ACR22 GLORIA Low steroid usage: lower DAS28, reduced joint damage BUT 24% increased adverse effects ⁦@RheumNow⁩ https://t.co/vYTAhoQEqr
      RT @ericdeinmd: Ab1012 #ACR22
      @AlexisOgdie Opioid Use & Healthcare Utilization in PsA and AS
      21% PsA pts on opioids

      Eric Dein ericdeinmd

      3 years 10 months ago
      Ab1012 #ACR22 @AlexisOgdie Opioid Use & Healthcare Utilization in PsA and AS 21% PsA pts on opioids, 27% AS on opioids Opioid users - more co-morbidities, 🚬, worse disease Tended to higher use of anti-rheumatic drugs Higher health care utilizations, medical $$ @RheumNow
      RT @ericdeinmd: @RheumNow Panel felt that weight and smoking recs were adequately covered by general health recommendati

      Eric Dein ericdeinmd

      3 years 10 months ago
      @RheumNow Panel felt that weight and smoking recs were adequately covered by general health recommendations BUT, this misses a HUGE opportunity to stress that inflammatory arthritis pts have higher risks and need greater emphasis on modifiable risk factors than gen pop #ACR22 @RheumNow
      Can I stop Methotrexate in RA?
      RT @uptoTate: CASIPSA results: CT SIJ characteristics from PsA pts similar to age- and sex-matched controls, but w/ high

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      CASIPSA results: CT SIJ characteristics from PsA pts similar to age- and sex-matched controls, but w/ higher prevalence of erosions, found in 18% of PsA patients. Abs 1012 #ACR22 https://t.co/jdUSUoUUbf https://t.co/2NQOhncYFc
      RT @drdavidliew: Look at these graphs and try and tell me that sex and gender doesn't matter in RA.

      We have seen in stu

      David Liew drdavidliew

      3 years 10 months ago
      Look at these graphs and try and tell me that sex and gender doesn't matter in RA. We have seen in study after study after study - sex and gender matters. ABST0241 @erasmusmcintl #ACR22 @RheumNow https://t.co/GQnKrAp0eB https://t.co/MxHRy2kwDN
      RT @drdavidliew: New IgG4-RD therapeutic avenues,
      mechanistically driven (B cell-CTL interaction):

      inebilizumab: regist

      David Liew drdavidliew

      3 years 10 months ago
      New IgG4-RD therapeutic avenues, mechanistically driven (B cell-CTL interaction): inebilizumab: registered for NMO, ph3 now obexelimab: novel dual MOA ?safer, ph3 now rilzabrutinib: BTKi, ph2 now elotuzumab: targets SLAMF7, MM registered, NIH study John Stone #ACR22 @RheumNow https://t.co/lx4bnCutlS
      RT @drdavidliew: Pre-RA studies: a summary by Dr. Deane #ACR22 @RheumNow https://t.co/HU8JWmYM8H

      David Liew drdavidliew

      3 years 10 months ago
      Pre-RA studies: a summary by Dr. Deane #ACR22 @RheumNow https://t.co/HU8JWmYM8H
      RT @drdavidliew: One of the nicest, smartest, and hardest working young rheumatologists you will meet, and I'm sure is d

      David Liew drdavidliew

      3 years 10 months ago
      One of the nicest, smartest, and hardest working young rheumatologists you will meet, and I'm sure is destined for great things. My hat off to you @SattuiSEMD, congratulations! #ACR22 @RheumNow https://t.co/dzHXeahsHT
      RT @drdavidliew: Is channelling bias a risk, because of treating clinicians 'protecting' pre-existing autoimmune dx pts:

      David Liew drdavidliew

      3 years 10 months ago
      Is channelling bias a risk, because of treating clinicians 'protecting' pre-existing autoimmune dx pts: maybe? Certainly in practice, these pts might get less combo immunoRx; this @mcgillu data would suggest so Much more to understand across tumor streams ABST0760 #ACR22 https://t.co/z1rhAJZ9gj
      RT @drdavidliew: What imaging modality is best in GCA?

      Dutch study: n=42
      ?GCA got all three of USS, PET/CT, MRI

      Overal

      David Liew drdavidliew

      3 years 10 months ago
      What imaging modality is best in GCA? Dutch study: n=42 ?GCA got all three of USS, PET/CT, MRI Overall performance basically the same between all three. Important details in 🧵 but reasonable to say you can be happy with whatever you’ve got! ABST1617 #ACR22 #ACRBest @RheumNow https://t.co/HGt0vW9Z38
      RT @AurelieRheumo: To propose early intervention in pre-clinical PsA we need to first identify pts!

      Eder et al. PRESTO

      Aurelie Najm AurelieRheumo

      3 years 10 months ago
      To propose early intervention in pre-clinical PsA we need to first identify pts! Eder et al. PRESTO Prediction of Psoriatic Arthritis Tool Dvlped 600+ Pso M stiff, PASI, nails, fatigue pain severity Sens 61% Spe 77% for 5% proba PsA onset w/in 5yrs Abs#1612 #ACR22 @Rheumnow https://t.co/QYOIKe3nui
      ×